- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02389777
ST266 in UV-induced Inflammation
May 9, 2019 updated by: Noveome Biotherapeutics, formerly Stemnion
Effect of ACCS in UV-induced Inflammation
This phase II clinical study will include fifteen healthy light skinned adult volunteers.
At screening subjects will be given a sunburn test.
This procedure involves exposing eight 1 square cm areas of skin over increasing doses of simulated solar radiation (SSR).
SSR is delivered by a 1,000-Watt xenon arc lamp, which emits ultraviolet wavelengths from 290-400 nm, closely resembling natural sunlight.
The Minimal Erythema Dose (MED) will be determined approximately 24 hours after initial exposure by using a chromometer.
The MED is calculated by linear regression.
Each test site is a one inch square area on the buttock or lower back.
Sites 1, 2, 3, 4, 5 will be irradiated with 2 MED of SSR.
Site 1 will not receive any ST266 treatment.
Sites 2 and 3 will be treated with ST266 immediately after irradiation.
8-12 hours later or at bedtime, Sites 2,3,4,5 with ST266 at home.
ST266 will also be applied 24 hours after SSR.
Between 24-36 hours after SSR, subject returns to the Skin Study Center for Minolta chromometer assessment of erythema at all test sites, as well as for high resolution digital photography (Canfield).
These assessments will be repeated at 48 hours and 72 hours post SSR.
Data will be graphed to quantify rate of erythema resolution.
Punch biopsies will be obtained at Site 1 (control) and Site 2 (SSR + immediate ST266 Rx).
If a difference in erythema is observed between Site 1 and Site 4, a biopsy will also be obtained from Site 4 (SSR + delayed ST266 Rx).
Biopsy samples will be tested using Reverse Transcriptase -Polymerase Chain Reaction (RT-PCR) and/or immunohistochemistry for markers of UV inflammation such as Interleukin (IL)-6, Tumor Necrosis Factor (TNF) -alpha, etc. Subjects will continue to apply the ST266 twice daily on Sites 3 and 5 until study visit 5.
An additional normal control skin biopsy may be performed in a subset of volunteers (4-5) to serve as reference control for the tissue analysis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This phase II clinical study will include ten to fifteen healthy light skinned adult volunteers who will be recruited through Institutional Review Board (IRB)-approved advertising.
At screening subjects will be given a sunburn test.
This procedure involves exposing eight 1 square cm areas of skin over increasing doses of simulated solar radiation (SSR), while the rest of the body is draped.
SSR is delivered by a 1,000-Watt xenon arc lamp, which emits ultraviolet wavelengths from 290-400 nm, closely resembling natural sunlight.
The Minimal Erythema Dose (MED) will be determined approximately 24 hours after initial exposure by using a chromometer that records the values of redness associated with each 1 square cm area exposed to the SSR the previous day.
Once the MED is calculated by linear regression, the actual UV exposure of test sites will be conducted.
A test site consists of a one inch square area on the buttock or lower back.
Sites 1, 2, 3, 4, 5 will be irradiated with 2 MED of SSR while the rest of the body is draped.
Site 1 will not receive any ST266 treatment at all.
Sites 2 and 3 will be treated by investigators with ST266 immediately after irradiation.
8-12 hours later or at bedtime, subject will treat Sites 2,3,4,5 with ST266 at home.
ST266 application will also be done by subject on Sites 2,3,4,5 the next morning approximately 24 hours after SSR.
Between 24-36 hours after SSR, subject returns to the Skin Study Center for Minolta chromometer assessment of erythema at all test sites, as well as for high resolution digital photography (Canfield).
These assessments will be repeated at 48 hours and 72 hours post SSR and data will be graphed to quantify rate of erythema resolution.
Punch biopsies will be obtained at Site 1 (control) and Site 2 (SSR + immediate ST266 Rx).
If a difference in erythema is observed between Site 1 and Site 4 (i.e. if even the delayed treatment seems to effectively decrease inflammation), a biopsy will also be obtained from Site 4 (SSR + delayed ST266 Rx).
These biopsy samples will be tested using RT-PCR and/or immunohistochemistry for markers of UV inflammation such as IL-6, TNF-alpha, etc.
The test sites that have been biopsied will no longer undergo chromometer assessment post biopsy because the inflammation from the biopsy itself may confound the erythema readings.
Meanwhile, subject will continue to apply the ST266 twice daily on Sites 3 and 5 until study visit 5.
An additional normal control skin biopsy may be performed in a subset of volunteers (4-5) to serve as reference control for the tissue analysis.
This will not be required of all volunteers.
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Ages 18 years or older
- Fitzpatrick Skin Type I-III
- In good general Adults health
Exclusion Criteria:
- Known history of photodermatosis or photosensitivity disorder such as systemic lupus or porphyria
- Tanning bed exposure within the last 4 weeks
- Current intake of known strong photosensitizers such as doxycycline/tetracycline family of antibiotics and thiazide diuretics
- Current intake of immunosuppressive drugs such as oral steroids.
- Cancer or known history of cancer within the last 5 years.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control UV burn
No treatment of the UV Light burn will be given
|
|
Active Comparator: ST266 treated UV burn immediately
ST266 will be applied topically immediately by spray to the UV light burn wound
|
ST266 will be applied immediately to the UV light burn wound topically by spray twice per day
|
Active Comparator: ST266 treated UV burn delayed
ST266 will be applied topically by spray to the UV light burn beginning 6 - 12 hours after the burn
|
ST266 will be applied to the UV light burn topically by spray twice per day beginning 6-12 hours after the burn
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Erythema resolution
Time Frame: 3 days
|
Erythema measured by Chromometer
|
3 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Skin punch biopsy
Time Frame: Baseline and end of study period (day 3)
|
Punch biopsy will be assessed by RT-PCR and immunohistochemistry for markers of inflammation IL-6 and TNF-alpha
|
Baseline and end of study period (day 3)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: David L Steed, MD, Noveome Biotherapeutics, formerly Stemnion
- Principal Investigator: Elma D Baron, MD, Cae Western Reserve University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2015
Primary Completion (Actual)
August 1, 2015
Study Completion (Actual)
August 1, 2015
Study Registration Dates
First Submitted
March 10, 2015
First Submitted That Met QC Criteria
March 16, 2015
First Posted (Estimate)
March 17, 2015
Study Record Updates
Last Update Posted (Actual)
May 15, 2019
Last Update Submitted That Met QC Criteria
May 9, 2019
Last Verified
May 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ST-06-14
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Skin Burns
-
Centre Hospitalier Régional Metz-ThionvilleCompleted
-
Meir Medical CenterUnknown
-
Milliken Healthcare Products, LLCU.S. Army Medical Research and Development Command; Criterium, Inc.CompletedBurns | Skin Burn Requiring Skin GraftUnited States
-
Assiut UniversityNot yet recruiting
-
Rabin Medical CenterCompletedBurn | Grafting, SkinIsrael
-
The Metis FoundationNot yet recruiting
-
The Metis FoundationNot yet recruiting
-
University of Kansas Medical CenterNot yet recruitingBurns | Skin Graft Complications
-
Centre hospitalier de l'Université de Montréal...CompletedSkin Burn ExtensiveCanada
-
University of California, IrvineNational Institute of General Medical Sciences (NIGMS)RecruitingSkin Burn MultipleUnited States
Clinical Trials on ST266 immediate
-
Noveome Biotherapeutics, formerly StemnionIQVIA BiotechCompletedCytokine Release SyndromeUnited States
-
Noveome Biotherapeutics, formerly StemnionParexelRecruitingNecrotizing EnterocolitisUnited States
-
Noveome Biotherapeutics, formerly StemnionTerminatedDiabetes | Third Degree BurnsUnited States
-
Noveome Biotherapeutics, formerly StemnionIQVIA BiotechTerminatedPersistent Corneal Epithelial DefectUnited States
-
Noveome Biotherapeutics, formerly StemnionCompletedOcular HypertensionUnited States
-
Noveome Biotherapeutics, formerly StemnionCompletedPeriodontal DiseaseUnited States
-
Noveome Biotherapeutics, formerly StemnionCompletedPersistent Corneal Epithelial DefectUnited States
-
Noveome Biotherapeutics, formerly StemnionTerminated
-
Noveome Biotherapeutics, formerly StemnionCompletedRadiation-induced DermatitisUnited States
-
Noveome Biotherapeutics, formerly StemnionCompletedAllergic ConjunctivitisUnited States